22 December 2025
22 December 2025
With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing deals.
Andexxa will no longer be sold or manufactured on US soil from 22 December.
Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.
MYQORZO is anticipated to be available in the US during the second half of January 2026.
MEDIPOST will supply drug substance and retain manufacturing rights, while exclusive rights for Japanese market will be managed by Teikoku Seiyaku.
The Trump Administration has emphasised the urgent need for accessible obesity treatments.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
